LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.74 USD Market Closed
Market Cap: 45.8m USD

LAVA Therapeutics NV
Gross Profit

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

LAVA Therapeutics NV
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Gross Profit
$12m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Gross Profit
$325.7m
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
31%
ProQR Therapeutics NV
NASDAQ:PRQR
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Gross Profit
$13.9m
CAGR 3-Years
-37%
CAGR 5-Years
N/A
CAGR 10-Years
13%
argenx SE
XBRU:ARGX
Gross Profit
$2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
45.8m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.52 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Gross Profit?
Gross Profit
12m USD

Based on the financial report for Dec 31, 2024, LAVA Therapeutics NV's Gross Profit amounts to 12m USD.

What is LAVA Therapeutics NV's Gross Profit growth rate?
Gross Profit CAGR 1Y
265%

Over the last year, the Gross Profit growth was 265%.

Back to Top